Clinical trial

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors…

NCT00118170 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00118170
Title Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
Official title Pharmacokinetic and Phase I Study of Sorafenib (BAY 43-9006, NSC 724772, IND 69896) for Solid Tumors and Hematologic Malignancies in Patients With Hepatic or Renal Dysfunction
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma and 36 more
Intervention type Drug, Other
Interventions sorafenib tosylate, pharmacological study
Enrollment 150
Start date Oct 1, 2004
Primary completion May 1, 2007
First posted Jul 11, 2005
Last update posted Jan 7, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies